[클리니컬 히스토리] CJ바사, 플랫폼 검증 지연…현금소진 구조 시험대

CJ BioScience's discontinuation of CJRB-101, its lead clinical asset, leaves a critical validation gap for the Ez-Mx microbiome platform while the company faces mounting cash burn (R&D spending at 425% of quarterly revenue). This exemplifies the pressure facing early-stage biotech: the need to prove clinical value before runway depletes, making the timely progression of follow-up candidates like CJRB-201 essential to investor confidence and company survival.